ALHC

Alignment HealthcareA

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$23.50

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$16.50

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$9.50

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-03

AI commentary

Primary operating evidence improved materially after Q2: the company reported strong growth, improved MBR, and higher FY26 guidance [#SEC-8K-2026-07-30]. However, post-print price action was decisively negative, analyst revisions are mixed, and recent legal-solicitation headlines remain prominent. Social, options, short-interest, and employee-sentiment data are unavailable; the deterministic prior remains negative, so this is a monitoring view rather than a high-conviction bullish signal.

RankAlpha Sentiment Codex - 2026-09-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-16eventSeptember investor conferences could clarify the investment cadenceMedium impact

Alignment lists Baird and Morgan Stanley healthcare conference appearances for September 15-16, 2026. Commentary on clinical hiring, market expansion, MBR seasonality, and the 2027 product strategy could improve or worsen forward visibility. Source: https://ir.alignmenthealth.com/

2026-09-30eventQ3 2026 operating delivery is the next testHigh impact

The company guides Q3 2026 revenue of $1.30-$1.32 billion, membership of 295,500-297,500, and adjusted EBITDA of $20-$30 million. Delivery near the guide would help validate the raised full-year outlook; the official IR release is confirmed through the SEC 8-K [#SEC-8K-2026-07-30]. Source: https://ir.alignmenthealth.com/news-releases/news-release-details/alignment-healthcare-reports-second-quarter-2026-results

2026-09-30catalystSecond-half margin and medical-cost pressureHigh impact

Management expects only about 30% of FY26 adjusted EBITDA in the second half, citing planned clinical investments, earlier hiring, flatter Part D seasonality, higher-acuity members, and a $6.5 million unfavorable prior-year development in Q2 [#PR-EARNINGS-2026-07-31]. The Q3 margin trough could keep earnings revisions and sentiment under pressure.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-03 • Updated nightlySource: Internal modelMethodology